HC Wainwright Has Pessimistic Outlook of MLTX Q1 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Analysts at HC Wainwright lowered their Q1 2026 earnings estimates for shares of MoonLake Immunotherapeutics in a note issued to investors on Monday, March 2nd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.86) for the quarter, down from their previous forecast of ($0.68). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q2 2026 earnings at ($0.77) EPS, Q3 2026 earnings at ($0.75) EPS, Q4 2026 earnings at ($0.72) EPS and FY2026 earnings at ($3.10) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.92) EPS for the quarter, hitting analysts’ consensus estimates of ($0.92). During the same quarter in the prior year, the business posted ($0.72) earnings per share.

Other analysts also recently issued research reports about the company. Zacks Research raised MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. BTIG Research boosted their price target on MoonLake Immunotherapeutics from $24.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, February 23rd. Royal Bank Of Canada upped their price objective on MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the stock a “sector perform” rating in a research note on Monday. Needham & Company LLC increased their price objective on MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a report on Monday, February 23rd. Finally, The Goldman Sachs Group cut shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and raised their target price for the company from $8.00 to $10.00 in a research note on Wednesday, January 14th. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat.com, MoonLake Immunotherapeutics presently has an average rating of “Hold” and a consensus target price of $27.85.

MoonLake Immunotherapeutics Trading Down 0.7%

Shares of NASDAQ:MLTX opened at $18.02 on Thursday. The company’s 50-day moving average price is $15.97 and its two-hundred day moving average price is $22.25. MoonLake Immunotherapeutics has a one year low of $5.95 and a one year high of $62.75. The company has a debt-to-equity ratio of 0.24, a current ratio of 9.27 and a quick ratio of 9.27. The stock has a market capitalization of $1.16 billion, a PE ratio of -5.12 and a beta of 1.20.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Cormorant Asset Management LP raised its holdings in shares of MoonLake Immunotherapeutics by 118.4% in the 4th quarter. Cormorant Asset Management LP now owns 4,355,433 shares of the company’s stock worth $57,405,000 after acquiring an additional 2,361,260 shares during the last quarter. Janus Henderson Group PLC boosted its stake in MoonLake Immunotherapeutics by 18,782.8% during the 4th quarter. Janus Henderson Group PLC now owns 2,095,988 shares of the company’s stock valued at $27,657,000 after purchasing an additional 2,084,888 shares during the last quarter. Logos Global Management LP bought a new stake in MoonLake Immunotherapeutics during the 4th quarter worth approximately $23,065,000. Alliancebernstein L.P. increased its holdings in MoonLake Immunotherapeutics by 17.8% during the 2nd quarter. Alliancebernstein L.P. now owns 1,138,022 shares of the company’s stock worth $53,715,000 after purchasing an additional 171,932 shares in the last quarter. Finally, Vivo Capital LLC purchased a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter worth approximately $13,180,000. 93.85% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other MoonLake Immunotherapeutics news, CEO Da Silva Jorge Santos sold 70,000 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $14.49, for a total transaction of $1,014,300.00. Following the completion of the sale, the chief executive officer owned 2,878,577 shares of the company’s stock, valued at $41,710,580.73. This trade represents a 2.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kristian Reich sold 72,908 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $14.43, for a total transaction of $1,052,062.44. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 402,908 shares of company stock worth $5,987,162. 12.02% of the stock is owned by company insiders.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.